Neuropace Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 47/207 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Neuropace Inc's Score
Industry at a Glance
Industry Ranking
47 / 207
Overall Ranking
147 / 4563
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
17.500
Target Price
+6.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Neuropace Inc Highlights
StrengthsRisks
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 75.54% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.91M.
Undervalued
The company’s latest PE is -21.36, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.14M shares, decreasing 8.66% quarter-over-quarter.
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Ticker SymbolNPCE
CompanyNeuropace Inc
CEOBecker (Joel D)
Websitehttps://www.neuropace.com/
FAQs
What is the current price of Neuropace Inc (NPCE)?
The current price of Neuropace Inc (NPCE) is 16.020.
What is the symbol of Neuropace Inc?
The ticker symbol of Neuropace Inc is NPCE.
What is the 52-week high of Neuropace Inc?
The 52-week high of Neuropace Inc is 18.975.
What is the 52-week low of Neuropace Inc?
The 52-week low of Neuropace Inc is 7.563.
What is the market capitalization of Neuropace Inc?
The market capitalization of Neuropace Inc is 533.16M.
What is the net income of Neuropace Inc?
The net income of Neuropace Inc is -27.14M.
Is Neuropace Inc (NPCE) currently rated as Buy, Hold, or Sell?
According to analysts, Neuropace Inc (NPCE) has an overall rating of Buy, with a price target of 17.500.
What is the Earnings Per Share (EPS TTM) of Neuropace Inc (NPCE)?
The Earnings Per Share (EPS TTM) of Neuropace Inc (NPCE) is -0.750.